Dyne Therapeutics Announces 2024 Annual Meeting of Stockholders on May 22

TL;DR

<b>Dyne Therapeutics will hold its 2024 virtual Annual Meeting on May 22, 2024, to elect directors and ratify auditors.</b>

AI Summary

Dyne Therapeutics, Inc. (DYN) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Dyne Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 22, 2024, at 8:00 a.m. ET. The meeting will include the election of three Class I directors: Carlo Incerti, M.D., Catherine Stehman-Breen, M.D., and John G. Cox. Stockholders will vote on the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2024. The meeting will be conducted exclusively online via www.proxydocs.com/DYN, requiring advance registration. Stockholders of record as of March 28, 2024, are entitled to vote.

Why It Matters

For investors and stakeholders tracking Dyne Therapeutics, Inc., this filing contains several important signals. This meeting is a key governance event where shareholders directly influence the company's leadership and financial oversight. The virtual format allows for broader participation but requires specific registration steps for shareholders to engage and vote.

Risk Assessment

Risk Level: low — Dyne Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.

Analyst Insight

Shareholders should review the director nominees and auditor ratification to make informed voting decisions before the May 22nd meeting.

Key Numbers

• 3 — Class I Directors (To be elected at the meeting)
• 2027 — Director Term Expiration (For elected directors)
• 2024 — Fiscal Year (For which auditors are being ratified)
• May 22, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting)
• March 28, 2024 — Record Date (Date to determine stockholder eligibility to vote)

Key Players & Entities

• Dyne Therapeutics, Inc. (company) — Registrant
• Carlo Incerti, M.D. (person) — Director nominee
• Catherine Stehman-Breen, M.D. (person) — Director nominee
• John G. Cox (person) — Director nominee
• Deloitte & Touche LLP (company) — Independent registered public accounting firm
• May 22, 2024 (date) — Date of Annual Meeting
• March 28, 2024 (date) — Record date for voting eligibility

FAQ

Industry Context

Dyne Therapeutics operates in the pharmaceutical preparations industry, focusing on developing therapies.

Regulatory Implications

This filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.

What Investors Should Do

1. Review the qualifications of the nominated directors for Class I.
2. Confirm the ratification of Deloitte & Touche LLP as the independent auditor for FY2024.
3. Register in advance to attend the virtual meeting and vote electronically.

Key Dates

• 2024-05-22: 2024 Annual Meeting of Stockholders — Key date for voting on directors and auditors.
• 2024-03-28: Record Date — Determines eligibility to vote at the annual meeting.

Year-Over-Year Comparison

This is the initial filing for the 2024 Annual Meeting of Stockholders, outlining the agenda and voting procedures.

Filing Documents

• 2024_proxy.htm (DEF 14A) — 879KB
• img73917039_0.jpg (GRAPHIC) — 46KB
• img73917039_1.jpg (GRAPHIC) — 754KB
• img73917039_2.jpg (GRAPHIC) — 337KB
• 0000950170-24-042276.txt (&nbsp;) — 2446KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 24 Summary Compensation Table 24 Narrative Disclosure to Summary Compensation Table 24 Outstanding Equity Awards at 2023 Fiscal Year-End 26 Employment and Other Arrangements with Our Named Executive Officers and Chief Executive Officer 28 401(k) Plan 30 Securities Authorized for Issuance Under Our Equity Compensation Plans 30 TRANSACTIONS WITH RELATED PERSONS 32

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 35 DELINQUENT SECTION 16(A) REPORTS 36 STOCKHOLDER PROPOSALS FOR OUR 2025 ANNUAL MEETING 37 HOUSEHOLDING OF ANNUAL MEETING MATERIALS 37 OTHER MATTERS 37 DYNE THERAPEUTICS, INC. 1560 Trapelo Road Waltham, Massachusetts 02451 (781) 786-8230 PROXY STATEMENT 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on Wednesday, May 22, 2024 INFORMATION CONCERNING SOLICITATION AND VOTING This proxy statement contains information about our 2024 Annual Meeting of Stockholders, or the Annual Meeting. The meeting will be held on Wednesday, May 22, 2024 at 8:00 a.m. Eastern Time. The Annual Meeting will be held exclusively via the Internet in a virtual meeting format at www.proxydocs.com/DYN . There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. Except where the context otherwise requires, references to &#x201c;Dyne,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; and similar terms refer to Dyne Therapeutics, Inc. References to our website are inactive textual references only and the contents of our website are not incorporated by reference into this proxy statement. This proxy statement and the enclosed proxy card are being furnished in connection with the solicitation of proxies by our board of directors for use at the Annual Meeting and at any adjournment or postponement of that meeting. All proxies will be voted in accordance with the instructions they contain. If you do not specify your voting instructions, your proxy will be voted in accordance with the recommendations of our board of directors. We are making this proxy statement, the related proxy card and our annual report to stockholders for the fiscal year ended December 31, 2023, or our 2023 Annual Report, available to stockholders for the first time on or about April 5, 2024. A copy of our Annual Report on F

View Full Filing

View this DEF 14A filing on SEC EDGAR